Zofran Lawsuits Transfered to U.S District Court. Zofran Lawsuits From Missisipi and Texas Transfered to U.S District Court. Two additional Zofran lawsuits, with plaintiffs from Mississippi and Texas, have been transferred to Zofran MDL 2675 pending in U.S. District Court of Massachusetts, before Judge F. Dennis Saylor, where the litigation has been consolidated for pre-trial proceedings.
There is now a total of 282 lawsuits against the multinational manufacturer of Zofran, GlaxoSmithKline, that have been consolidated in the Boston federal court.
Zofran was initially approved by the U.S. Food and Drug Administration (FDA) to treat nausea and vomiting among cancer patients. The FDA has never approved the potent anti-nausea drug Zofran for the treatment of morning sickness. New studies have revealed that not only is Zofran unsafe for use in pregnant women, but may actually cause major birth defects in infants.
Plaintiffs maintain that GlaxoSmithKline never made the study, including the side effect risks, public. The allegations continue stating GlaxoSmithKline not only choosing to not curb Zofran’s use during pregnancy, but actually marketing Zofran specifically as a morning sickness treatment.
Prenatal exposure to a generic version of Zofran led her child
The plaintiff from Mississippi says that prenatal exposure to a generic version of Zofran led her child, who is now 3, to have many congenital abnormalities. The mother lists at least 13 serious fetal birth defects including skeletal muscle atrophy and cardiomegaly, an abnormally enlarged heart.
The second Texas lawsuit claims that a generic form of Zofran’s active ingredient, ondansetron, caused her unborn child to develop cardiac septal defects. The mother names specifically two “hole in the heart” abnormalities, atrial septal defect and ventricular septal defect.
Harvard University researchers have associated the drug to an increased risk for cleft palate. Researchers in Europe have found a link with congenital heart defects and Zofran. Danish researchers found that ondansetron, Zofran’s active ingredient, could raise the risk for cardiac septal defects by 200 percent to 400 percent